Rituxan (rituximab) - Roche
Beyond Minimal Change: A Hidden Diagnosis of Hereditary Transthyretin Amyloidosis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0781; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description A 30-year-old female with presumed minimal change disease had persistent nephrotic syndrome despite treatment with corticosteroids, tacrolimus, and later rituximab...Renal involvement in p.Val142Ile carriers is uncommon and not a typical feature of this variant. Kidney disease in TTR amyloidosis is most strongly associated with the Val30Met variant, not Val142Ile highlighting the value of this case." 
Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Immunology • Nephrology • Renal Disease
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4550378
 
Jackeline Flores; Asmaa Beltagy; Addie Flowers; Piruthiviraj Natarajan; Camilo Pena
 
Oct 2, 2026
 
Prev Next